Mukai, S.; Yamasaki, K.; Fujii, M.; Nagai, T.; Terada, N.; Kataoka, H.; Kamoto, T.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. Int. J. Mol. Sci. 2020, 21, 2663.
https://doi.org/10.3390/ijms21082663
AMA Style
Mukai S, Yamasaki K, Fujii M, Nagai T, Terada N, Kataoka H, Kamoto T.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. International Journal of Molecular Sciences. 2020; 21(8):2663.
https://doi.org/10.3390/ijms21082663
Chicago/Turabian Style
Mukai, Shoichiro, Koji Yamasaki, Masato Fujii, Takahiro Nagai, Naoki Terada, Hiroaki Kataoka, and Toshiyuki Kamoto.
2020. "Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers" International Journal of Molecular Sciences 21, no. 8: 2663.
https://doi.org/10.3390/ijms21082663
APA Style
Mukai, S., Yamasaki, K., Fujii, M., Nagai, T., Terada, N., Kataoka, H., & Kamoto, T.
(2020). Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. International Journal of Molecular Sciences, 21(8), 2663.
https://doi.org/10.3390/ijms21082663
